(Q34356149)

1 August 2017

Liquid biopsy: monitoring cancer-genetics in the blood (English)

1 reference

1 August 2017

0 references

0 references

Federica Di Nicolantonio

2

object named as

Federica Di Nicolantonio

0 references

Fotios Loupakis

object named as

Fotios Loupakis

3

0 references

Alberto Bardelli

object named as

Alberto Bardelli

4

0 references

author name string

Emily Crowley

1

1 reference

PubMed ID

23836314

1 August 2017

language of work or name

English

0 references

publication date

9 July 2013

1 reference

Nature Reviews Clinical Oncology

1 August 2017

1 reference

1 August 2017

10

1 reference

1 August 2017

472-484

1 reference

1 August 2017

8

1 reference

Fine-needle aspiration (FNA) biopsy: historical aspects.

1 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Tumour seeding following percutaneous needle biopsy: the real story!

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Review: incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

The Occurrence of Single-Stranded DNA in the Serum of Patients with Systemic Lupus Erythematosus and Other Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Cell-free DNA in the blood as a solid tumor biomarker--a critical appraisal of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Cell-free nucleic acids as biomarkers in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

The origin of extracellular DNA during the clearance of dead and dying cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Autoimmunity versus tolerance: can dying cells tip the balance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

About the possible origin and mechanism of circulating DNA apoptosis and active DNA release

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Excretion of deoxyribonucleic acid by lymphocytes stimulated with phytohemagglutinin or antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Cell-free nucleic acids circulating in the plasma of colorectal cancer patients induce the oncogenic transformation of susceptible cultured cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Cancer progression mediated by horizontal gene transfer in an in vivo model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Circulating cell-free nucleic acids: promising biomarkers of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Parameters of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Circulating mutant DNA to assess tumor dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Analysis of circulating tumor DNA to monitor metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

High fragmentation characterizes tumour-derived circulating DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Microsatellite alterations in plasma DNA of small cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Detection and quantification of mutations in the plasma of patients with colorectal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Circulating tumour markers can define patients with normal colons, benign polyps, and cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Translational genomics: the challenge of developing cancer biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Effect of fixatives and tissue processing on the content and integrity of nucleic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Quantitative analysis of plasma DNA in colorectal cancer patients: a novel prognostic tool.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Monitoring of circulating tumour-associated DNA as a prognostic tool for oral squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Gene expression profiling predicts clinical outcome of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Neuroblastoma: biological insights into a clinical enigma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Influence of neuroblastoma stage on serum-based detection of MYCN amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Is computed tomography follow-up of patients after lobectomy for non-small cell lung cancer of benefit in terms of survival?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Controversies in clinical cancer dormancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Genomic analysis of circulating cell-free DNA infers breast cancer dormancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Roles for KRAS in pancreatic tumor development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

APC mutations occur early during colorectal tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Mutational analysis of the tyrosine kinome in colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

ALK in lung cancer: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Implementing personalized cancer genomics in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Noninvasive detection of HER2 amplification with plasma DNA digital PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Targeted therapies: how personal should we go?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Mutations in UVSSA cause UV-sensitive syndrome and destabilize ERCC6 in transcription-coupled DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Detection of HER2 amplification in circulating free DNA in patients with breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Med1 plays a critical role in the development of tamoxifen resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Cross-talk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Tailoring to RB: tumour suppressor status and therapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Aurora-A promotes gefitinib resistance via a NF-κB signaling pathway in p53 knockdown lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Applying strategies from libertarian paternalism to decision making for prostate specific antigen (PSA) screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Cancer cell adaptation to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Comparison of KRAS Mutation Assessment in Tumor DNA and Circulating Free DNA in Plasma and Serum Samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Identification of loss of heterozygosity on circulating free DNA in peripheral blood of prostate cancer patients: potential and technical improvements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Analysis of cancer mutation signatures in blood by a novel ultra-sensitive assay: monitoring of therapy or recurrence in non-metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Cell-free DNA is released from tumor cells upon cell death: a study of tissue cultures of tumor cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Isolation and Extraction of Circulating Tumor DNA from Patients with Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Detection of mutated BRAFV600E variant in circulating DNA of stage III–IV melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Fate of Injected Deoxyribonucleic Acid in Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Nucleic acids spontaneously released by living frog auricles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Persistence of tumor DNA in plasma of breast cancer patients after mastectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Circulating MYCN DNA predicts MYCN-amplification in neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Follow-up strategies for patients treated for non-metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

K-ras Mutations in Circulating DNA From Pancreatic and Lung Cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Codon 249 mutation in exon 7 of p53 gene in plasma DNA: maybe a new early diagnostic marker of hepatocellular carcinoma in Qidong risk area, China

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Complete pathologic response in lung tumors in two patients with metastatic non-small cell lung cancer treated with erlotinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Preferential isolation of fragmented DNA enhances the detection of circulating mutated k-ras DNA

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

The importance of careful blood processing in isolation of cell-free DNA

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

The concentration of deoxyribonucleic acid in plasma from 73 patients with colorectal cancer and apparent clinical correlations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Potential clinical significance of plasma-based KRAS mutation analysis using the COLD-PCR/TaqMan(®) -MGB probe genotyping method

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

Next-generation sequencing entering the clinical arena

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.110

31 March 2020

1 reference

12 December 2020

Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features.

1 reference

12 December 2020

Spontaneous release of DNA by human blood lymphocytes as shown in an in vitro system

1 reference

12 December 2020

Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer

1 reference

12 December 2020

Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients

1 reference

12 December 2020

Detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer.

1 reference

12 December 2020

Difference between free circulating plasma and serum DNA in patients with colorectal liver metastases

1 reference

12 December 2020

DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells.

1 reference

12 December 2020

Primary colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up

1 reference

12 December 2020

Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival

1 reference

12 December 2020

A review of studies on the detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer

1 reference

12 December 2020

Molecular detection of APC, K- ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers.

1 reference

12 December 2020

Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients

1 reference

12 December 2020

Microsatellite analysis of serum DNA in patients with oral squamous cell carcinoma.

1 reference

12 December 2020

APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.

1 reference

12 December 2020

10.1038/NRCLINONC.2013.110

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

23836314